ResearcherUniversity of CincinnatiNo recent work listed

Weiwei Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6802-1647; OpenAlex author ID A5088705068. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2022: 1 paper

Papers 1

Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunoc… Co-author DOI 10.3390/cancers14112618 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gregory C. Wilson · 1 shared paper, 2022 · strength 0.15
- Paper Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancre… DOI 10.3390/cancers14112618 ↗
Erich Gulbins · 1 shared paper, 2022 · strength 0.15
- Paper Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancre… DOI 10.3390/cancers14112618 ↗
Syed Ameen Ahmad · 1 shared paper, 2022 · strength 0.15
- Paper Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancre… DOI 10.3390/cancers14112618 ↗
Sameer H. Patel · 1 shared paper, 2022 · strength 0.15
- Paper Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancre… DOI 10.3390/cancers14112618 ↗
Ildikò Szabó · 1 shared paper, 2022 · strength 0.15
- Paper Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancre… DOI 10.3390/cancers14112618 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.